Robert Gould, Fulcrum Therapeutics interim CEO
January 18, 2023 07:50 AM ESTUpdated 02:15 PM
Financing
R&D

With CEO search, PhI­II study un­der­way, Ful­crum Ther­a­peu­tics rais­es $125M from stock of­fer­ing

Katherine Lewin

News Reporter

Who­ev­er be­comes the next CEO of Ful­crum Ther­a­peu­tics will have $125 mil­lion more to work with.

The com­pa­ny is sell­ing off …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times